Literature DB >> 31066092

Baseline predictors influencing the prognosis of invasive aspergillosis in adults.

Philipp Koehler1,2, Jon Salmanton-García1, Stefanie K Gräfe2, Felix C Koehler2, Sibylle C Mellinghoff1,2,3, Danila Seidel1,2, Angela Steinbach2,3, Oliver A Cornely1,2,3,4.   

Abstract

Invasive aspergillosis (IA) is a serious hazard to haematological and critical care patients. Impactful risk factors for developing IA have been characterised; however, systematic analysis of baseline prognostic factors for treatment course of IA is missing. To understand prognostic variables, we analysed original articles identifying baseline factors that predict treatment outcome in patients with IA. PubMed database was searched for publications since database inception until May 2018. Inclusion criteria were published baseline prognostic factors present at the diagnosis of IA. In total, 58 studies from 267 centres reported 7320 patients with IA and 40 different predictors. Unfavourable predictors in medical history were kidney (7.4%, 10/136) and liver failure (3.7%, 5/136), ICU admission (3.7%, 5/136) and uncontrolled underlying disease (3.7%, 5/136). Regarding state of immunosuppression, negative outcome predictors were prolonged neutropenia (12.5%, 17/136), corticosteroid treatment (8.1%, 11/136) and graft-vs-host disease (3.7%, 5/136). On the pathogen side, relevant predictors were galactomannan positivity (8.1%, 11/136), Aspergillus terreus infection (2.2%, 3/136) and lack of amphotericin B susceptibility (1.5%, 2/136). IA-specific predictors were disseminated disease (5.1%, 7/136) and CNS involvement (2.9%, 4/136). Imaging results associated with negative outcome were multiple consolidations (2.9%, 4/136), bipulmonary lesions (2.2%, 3/136) and pleural effusion (2.2%, 3/136). At diagnosis of IA, most frequently identified predictors of outcome were neutropenia, corticosteroid use, elevated galactomannan, renal failure and disseminated disease. The predictors may be used to identify patients at high risk for treatment failure and to stratify neglected patient groups for clinical trials.
© 2019 Blackwell Verlag GmbH.

Entities:  

Keywords:  clinical trials; corticosteroids; disseminated disease; galactomannan; immunosuppression; intensive care unit; invasive fungal disease; neutropenia

Mesh:

Substances:

Year:  2019        PMID: 31066092     DOI: 10.1111/myc.12926

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  4 in total

1.  Two entities in pulmonary nodules of a diabetic patient receiving corticosteroid therapy for bullous pemphigoid: an autopsy case report.

Authors:  Reimi Mizushima; Kotaro Haruhara; Nei Fukasawa; Mari Satake; Akira Fukui; Kentaro Koike; Nobuo Tsuboi; Hiroyuki Takahashi; Takashi Yokoo
Journal:  BMC Infect Dis       Date:  2022-07-07       Impact factor: 3.667

2.  A retrospective multi-center study of treatment, outcome, and prognostic factors in 34 dogs with disseminated aspergillosis in Australia.

Authors:  Yi Yu Lim; Caroline Mansfield; Mark Stevenson; Mary Thompson; David Davies; Joanna Whitney; Fleur James; Anna Tebb; Darren Fry; Sibylle Buob; Lydia Hambrook; Gladys Boo; Julien R S Dandrieux
Journal:  J Vet Intern Med       Date:  2022-01-27       Impact factor: 3.333

3.  Clinical Characteristics and Prognostic Risk Factors of Patients With Proven Invasive Pulmonary Aspergillosis: A Single-Institution Retrospective Study.

Authors:  Xiang Tong; Tao Liu; Kexin Jiang; Dongguang Wang; Sitong Liu; Ye Wang; Hong Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-23

4.  No time for pending confirmation of invasive fungal disease in critically ill COVID-19 patients-think empirical treatment.

Authors:  Anne-Lise Bienvenu; Nathalie Bleyzac; Jean-Christophe Richard; Gilles Leboucher
Journal:  Crit Care       Date:  2020-09-29       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.